Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIdox Group Regulatory News (IDOX)

  • There is currently no data for IDOX

Half Year Trading Update

19 May 2020 07:00

RNS Number : 2652N
IDOX PLC
19 May 2020
 

19 May 2020

Idox plc

('Idox', 'We' or the 'Group')

FY20 H1 Trading Update

 

ldox plc (AIM: IDOX), a leading supplier of specialist information management software and solutions to the public and asset intensive sectors, is pleased to issue a trading update in respect of the first half of its financial year, the six months ended 30 April 2020 ("FY20 H1").

 

Idox continues to make strong progress across all its activities and expects to report results for FY20 H1 in line with the Board's expectations.

 

Financial Summary

The Group expects to report the following results for FY20 H1:

· Revenue of £35.1m (2019 H1: £31.0m restated1), an increase of 13% (10% organic).

· Adjusted EBITDA2 of £9.6m (2019 H1: £4.1m restated1), a significant increase of 138%. Adjusted EBITDA2 margin improved to 27% (2019 H1: 13%, restated1).

· Net debt at 30 April 2020 of £14.3m (30 April 2019: £25.4m, 31 Oct 2019: £26.4m), a significant decrease, giving a net debt to EBITDA ratio of 0.7 (net debt / trailing 12 months Adjusted EBITDA).

 

1 2019 H1 figures restated as disclosed in the FY19 Annual Report.

2 Adjusted EBITDA is defined as earnings before amortisation, depreciation, restructuring, acquisition, corporate finance and share option costs.

 

'Four Pillars' programme

We are pleased to advise on our progress across the Group in the following areas:

· Revenue enhancement - we continue to improve sales governance and execution, including analysing in detail the revenue opportunities in our existing customer base and markets. During the period we have gone live with the Group's first ever business-wide CRM and have consolidated all the Group's marketing activities.

· Margin enhancement - we are consolidating common operations and identifying opportunities to move customers and products to the cloud to drive long-term margins. During the period we have completed the consolidation of the Group's nine customer support desks to a single support portal and are firmly on track with the integration of Tascomi, which was acquired in July 2019.

· Communication - During the period we completed the Group's first ever business-wide roadshow directly presenting to two-thirds of all employees and have increased regular employee engagement during lockdown.

· Organisation simplicity - we have streamlined the Group's activities and responded to employee feedback to remove unnecessary organisational complexity. During the period (and prior to the pandemic) we have exited all operations in Malta and the Republic of Ireland, which were sub-scale, and are in the process of consolidating our UK operations to a single entity to drive further efficiencies.

 

 

Notice of Results

The Group expects to report its FY20 H1 results on Monday 15 June 2020. Management intends to host a results webinar on the day. Please contact MHP Communications to register your interest.

 

Covid-19 Pandemic

The Group continues to regularly assess the impact of the Covid-19 pandemic on its immediate trading and longer-term prospects. The assessments performed and disclosed in our FY19 results in early April 2020 remain valid and the current year financial performance is expected to be in line with existing expectations. As planned, Idox has not needed to participate in any government job retention schemes.

 

Idox has benefitted from the fact that its business model has, for a number of years, included a large number of employees operating remotely. Therefore the move to home working across the Group was seamless and readily adopted and has ensured we have had suitable structures in place to monitor employee health and wellbeing.

 

The Group continues to manage carefully the exposures identified, and support our health, local authority and private sector customers to deal with the ongoing impacts arising from the pandemic.

 

David Meaden, Chief Executive of Idox said:

"Idox has delivered revenue growth and visibility, improved margins and strong cash generation. We have focused our efforts around our 'four pillars' programme to improve revenue, margins, communication and organisational simplicity.

 

"We are now in our 'run' phase, having created a stable baseline of profitable growth and having executed our business plan with greater focus and discipline during the 'walk' phase last year; we are building real momentum across the Group to create value for employees, shareholders and other partners.

 

"The Group has successfully risen to the challenges caused by the Covid-19 pandemic. Our core business model of home working and focus on the public sector means Idox is well placed to deal with the unfolding impacts of Covid-19. We continue to manage the exposures in the business, and support our customers, employees and wider communities. Consequently, we remain cautiously optimistic about the future."

 

 

For further information please contact:

 

Idox plc

+44 (0) 870 333 7101

Chris Stone, Non-Executive Chairman

 

David Meaden, Chief Executive

 

Rob Grubb, Chief Financial Officer

 

 

 

Peel Hunt LLP (NOMAD and Broker)

+44 (0) 20 7418 8900

Edward Knight

 

Nick Prowting

 

James Steel

 

 

 

MHP Communications

+ 44 (0) 203 128 8100

Reg Hoare

 idox@mhpc.com

James Bavister

 

Amy O'Sullivan

 

 

About Idox plc

For more information see www.idoxplc.com @Idoxgroup 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTKKFBKOBKDPPD
Date   Source Headline
24th Apr 20184:32 pmRNSHolding(s) in Company
24th Apr 201810:24 amRNSHolding(s) in Company
23rd Apr 20183:40 pmRNSHolding(s) in Company
19th Apr 20183:58 pmRNSResult of AGM and Board Change
19th Apr 20183:54 pmRNSAGM Statement and Trading Update
19th Apr 20187:00 amRNSAGM Statement and Trading Update
27th Mar 20185:17 pmRNSDirector/PDMR Shareholding
27th Mar 201811:02 amRNSPosting of Annual Report and Notice of AGM
22nd Mar 20185:27 pmRNSHolding(s) in Company
19th Mar 201811:22 amRNSHolding(s) in Company
15th Mar 20185:17 pmRNSVesting of LTIP
8th Mar 20184:43 pmRNSHolding(s) in Company
1st Mar 201812:25 pmRNSDirectorate Change
1st Mar 201811:30 amRNSHolding(s) in Company
1st Mar 20187:00 amRNSFinal Results
20th Feb 201812:24 pmRNSHolding(s) in Company
2nd Feb 20184:12 pmRNSHolding(s) in Company
2nd Feb 20188:58 amRNSHolding(s) in Company
31st Jan 20184:52 pmRNSHolding(s) in Company
25th Jan 201812:34 pmRNSDirector/PDMR Shareholding
5th Jan 20184:40 pmRNSSecond Price Monitoring Extn
5th Jan 20184:35 pmRNSPrice Monitoring Extension
3rd Jan 201810:51 amRNSHolding(s) in Company
27th Dec 20171:48 pmRNSHolding(s) in Company
13th Dec 20177:00 amRNSYear End Update and Board Change
14th Nov 20173:45 pmRNSYear End Trading Update
2nd Nov 20171:31 pmRNSDirector Update
22nd Sep 20172:33 pmRNSExercise of Options and Total Voting Rights
20th Sep 20179:32 amRNSHolding(s) in Company
4th Sep 201710:38 amRNSDirectors' Dealing, Exercise of Options & TVR
1st Sep 20176:16 pmRNSHolding(s) in Company
23rd Aug 20176:06 pmRNSHolding(s) in Company
17th Aug 20177:00 amRNSAcquisition
4th Aug 20174:20 pmRNSDirector and PCA Dealing
14th Jul 20173:52 pmRNSDirector/PDMR Shareholding
6th Jul 20174:35 pmRNSPrice Monitoring Extension
29th Jun 20175:23 pmRNSDirector/PDMR Shareholding and Total Voting Rights
6th Jun 20177:00 amRNSHalf-year Report
18th May 20177:00 amRNSHalf Year Trading Update and Notice of Results
17th May 20174:31 pmRNSHolding(s) in Company
18th Apr 20173:45 pmRNSDirector/PDMR Shareholding and Total Voting Rights
7th Apr 20172:27 pmRNSDirector/PDMR Shareholding
22nd Mar 20179:22 amRNSDirector and PCA Dealing
24th Feb 201712:53 pmRNSResult of AGM
24th Feb 20177:00 amRNSAGM Trading Update
15th Feb 20172:55 pmRNSHolding(s) in Company
14th Feb 20171:24 pmRNSExercise of Options and Total Voting Rights
10th Feb 20173:39 pmRNSDirector/PDMR Shareholding
6th Feb 20176:30 pmRNSDirector/PDMR Shareholding
3rd Feb 20179:48 amRNSDirectors' Dealing, Exercise of Options and TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.